LUPIN
|
LUPIN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 116.64 | 71.87 | 42.01 | 9.45 | -33.62 |
| CEPS(Rs) | 147.22 | 98.02 | 68.74 | 29.20 | 3.29 |
| DPS(Rs) | 18.00 | 12.00 | 8.00 | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 489.59 | 374.93 | 311.08 | 270.67 | 263.84 |
| Tax Rate(%) | 22.07 | 17.65 | 20.09 | 37.52 | -9.99 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.93 | 14.19 | 11.94 | 6.05 | 0.73 |
| EBIT Margin(%) | 16.95 | 11.59 | 8.61 | 3.48 | -4.14 |
| Pre Tax Margin(%) | 15.94 | 10.80 | 7.63 | 2.52 | -4.62 |
| PAT Margin (%) | 12.42 | 8.89 | 6.10 | 1.57 | -5.09 |
| Cash Profit Margin (%) | 15.61 | 12.04 | 9.87 | 4.67 | 0.50 |
| Performance Ratios | |||||
| ROA(%) | 16.12 | 12.63 | 8.33 | 2.01 | -6.70 |
| ROE(%) | 27.11 | 21.13 | 14.61 | 3.68 | -11.79 |
| ROCE(%) | 28.86 | 21.97 | 16.24 | 6.06 | -7.11 |
| Asset Turnover(x) | 1.30 | 1.42 | 1.37 | 1.28 | 1.32 |
| Sales/Fixed Asset(x) | 1.99 | 1.87 | 1.68 | 1.67 | 1.93 |
| Working Capital/Sales(x) | 3.79 | 4.74 | 6.42 | 8.93 | 7.10 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.54 | 0.59 | 0.60 | 0.52 |
| Receivable days | 51.23 | 50.00 | 52.75 | 56.09 | 53.73 |
| Inventory Days | 48.93 | 51.19 | 54.32 | 58.53 | 53.64 |
| Payable days | 205.75 | 185.58 | 177.49 | 144.07 | 132.55 |
| Valuation Parameters | |||||
| PER(x) | 19.83 | 28.20 | 38.51 | 68.54 | - |
| PCE(x) | 15.71 | 20.67 | 23.54 | 22.19 | 227.04 |
| Price/Book(x) | 4.72 | 5.40 | 5.20 | 2.39 | 2.83 |
| Yield(%) | 0.78 | 0.59 | 0.49 | 0.62 | 0.54 |
| EV/Net Sales(x) | 3.79 | 4.16 | 3.76 | 1.95 | 2.23 |
| EV/Core EBITDA(x) | 11.47 | 17.24 | 19.13 | 17.33 | 85.46 |
| EV/EBIT(x) | 14.51 | 21.92 | 27.50 | 32.73 | -29.81 |
| EV/CE(x) | 3.74 | 4.24 | 4.43 | 1.94 | 1.69 |
| M Cap / Sales | 3.78 | 4.07 | 3.68 | 1.77 | 2.07 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 23.12 | 13.48 | 20.25 | 1.44 | 8.19 |
| Core EBITDA Growth(%) | 68.65 | 39.39 | 110.03 | 336.33 | -84.13 |
| EBIT Growth(%) | 69.54 | 57.65 | 175.93 | 180.59 | -167.66 |
| PAT Growth(%) | 61.98 | 70.82 | 332.35 | 129.66 | -222.92 |
| EPS Growth(%) | 62.29 | 71.07 | 344.46 | 128.11 | -225.39 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.26 | 0.30 | 0.19 | 0.34 | 0.32 |
| Current Ratio(x) | 1.90 | 1.87 | 1.58 | 1.34 | 1.51 |
| Quick Ratio(x) | 1.42 | 1.26 | 1.00 | 0.86 | 0.95 |
| Interest Cover(x) | 16.82 | 14.62 | 8.77 | 3.61 | -8.61 |
| Total Debt/Mcap(x) | 0.06 | 0.05 | 0.04 | 0.14 | 0.11 |
Compare Financial Ratios of peers of LUPIN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LUPIN | ₹108,331.3 Cr | -4.4% | 0.1% | 22.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,711.0 Cr | -0.8% | 3.5% | 14.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,376.0 Cr | -1% | 7.3% | 7.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,655.0 Cr | -0.9% | 10.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹113,979.0 Cr | -2.1% | -1.8% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,204.7 Cr | -5.8% | -13.2% | -7.7% | Stock Analytics | |
LUPIN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | -4.4% |
0.1% |
22.5% |
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses